Madrigal CMO sells 1,042 shares at $495.74

Madrigal Pharmaceuticals Chief Medical Officer David Soergel reported an open-market sale of 1,042 shares of the company’s Common Stock on June 1, 2026 at an average price of $495.74 per share.

Rhea-AI Filing Summary

Madrigal Pharmaceuticals Chief Medical Officer David Soergel reported an open-market sale of 1,042 shares of the company’s Common Stock on June 1, 2026 at an average price of $495.74 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 2, 2026, indicating it was pre-arranged. Following this sale, Soergel directly holds 10,033 shares of Madrigal Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 1,042 shares

Net Sell 1 txn

Insider Soergel David

Role Chief Medical Officer

Sold 1,042 shs ($517K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,042	$495.74	$517K

Holdings After Transaction: Common Stock — 10,033 shares (Direct)

Footnotes (1)

1. F1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.

Key Figures

Shares sold: 1,042 shares Sale price per share: $495.74 per share Shares held after transaction: 10,033 shares +1 more

4 metrics

Shares sold 1,042 shares Open-market sale of Common Stock on June 1, 2026

Sale price per share $495.74 per share Average price for 1,042 shares sold

Shares held after transaction 10,033 shares Direct ownership following June 1, 2026 sale

Net shares sold 1,042 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan financial

"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MDGL’s Chief Medical Officer report?

Madrigal Pharmaceuticals’ Chief Medical Officer, David Soergel, reported selling 1,042 shares of Common Stock. The shares were sold in an open-market transaction at an average price of $495.74 per share, as disclosed in a Form 4 insider filing.

At what price did David Soergel sell Madrigal (MDGL) shares?

David Soergel sold 1,042 Madrigal Pharmaceuticals shares at an average price of $495.74. This price reflects the per-share consideration received in the open-market transaction reported in the Form 4 insider filing for June 1, 2026.

How many MDGL shares does David Soergel hold after this Form 4 sale?

After selling 1,042 shares, David Soergel directly holds 10,033 shares of Madrigal Pharmaceuticals Common Stock. This post-transaction ownership figure is reported in the Form 4 and reflects his remaining direct equity stake following the sale.

Was the MDGL insider sale by David Soergel under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sale was effected under a Rule 10b5-1 trading plan adopted on March 2, 2026. Such pre-arranged plans are designed to allow scheduled trades independent of day-to-day market developments.

What type of transaction is reported in this Madrigal (MDGL) Form 4?

The Form 4 reports an open-market sale of Common Stock, coded as “S” for sale. It covers a single non-derivative transaction where 1,042 shares were sold, and details Soergel’s direct share balance after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 07:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soergel David

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 200

(Street)

WEST CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		1,042	D	$495.74	10,033	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)